Peter Lawson
Stock Analyst at Barclays
(2.07)
# 1,550
Out of 4,412 analysts
74
Total ratings
38.71%
Success rate
-6.67%
Average return
Main Sectors:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Downgrades: Equal-Weight | $25 | $23.70 | +5.49% | 4 | Apr 11, 2024 | |
| MGNX MacroGenics | Maintains: Overweight | $23 → $25 | $14.56 | +71.70% | 5 | Mar 8, 2024 | |
| TCRX TScan Therapeutics | Maintains: Overweight | $7 → $9 | $7.32 | +22.95% | 1 | Mar 7, 2024 | |
| ARVN Arvinas | Maintains: Overweight | $26 → $60 | $32.37 | +85.36% | 5 | Feb 29, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $18 → $22 | $11.64 | +89.00% | 4 | Feb 29, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Overweight | $47 → $63 | $45.53 | +38.37% | 3 | Feb 29, 2024 | |
| FATE Fate Therapeutics | Maintains: Overweight | $6 → $10 | $3.80 | +163.16% | 3 | Feb 27, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $58 → $70 | $93.00 | -24.73% | 7 | Feb 13, 2024 | |
| REPL Replimune Group | Maintains: Overweight | $50 → $13 | $6.42 | +102.49% | 2 | Dec 6, 2023 | |
| EXAI Exscientia | Maintains: Overweight | $12 → $10 | $4.03 | +148.14% | 2 | Oct 17, 2023 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $2 → $1 | $1.08 | -6.98% | 2 | Aug 10, 2023 | |
| PRLD Prelude Therapeutics | Maintains: Equal-Weight | $7 → $5 | $4.07 | +22.85% | 4 | Aug 4, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $31 → $34 | $21.06 | +61.44% | 2 | Jul 26, 2023 | |
| BMEA Biomea Fusion | Initiates: Overweight | $50 | $10.78 | +363.82% | 1 | May 12, 2023 | |
| RLAY Relay Therapeutics | Maintains: Equal-Weight | $23 → $15 | $6.37 | +135.48% | 2 | Apr 19, 2023 | |
| NRIX Nurix Therapeutics | Initiates: Overweight | $20 | $12.36 | +61.81% | 1 | Mar 9, 2023 | |
| DCPH Deciphera Pharmaceuticals | Maintains: Underweight | $8 → $9 | $14.65 | -38.57% | 5 | Jan 4, 2023 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $60 → $35 | $15.55 | +125.08% | 4 | Dec 21, 2022 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $80 | $58.46 | +36.85% | 1 | Nov 30, 2022 | |
| NEXI NexImmune | Maintains: Overweight | $175 → $50 | $3.37 | +1,383.68% | 2 | Aug 16, 2022 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $14 → $8 | $1.06 | +654.72% | 2 | Aug 5, 2022 | |
| BCYC Bicycle Therapeutics | Initiates: Overweight | $30 | $22.73 | +31.98% | 1 | Jul 28, 2022 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $7 → $3.5 | $1.59 | +120.13% | 3 | Jul 7, 2022 | |
| ILMN Illumina | Maintains: Underweight | n/a | $122.28 | - | 1 | Aug 6, 2021 | |
| AGIO Agios Pharmaceuticals | Upgrades: Overweight | n/a | $31.49 | - | 2 | Oct 22, 2020 | |
| XNCR Xencor | Initiates: Underweight | n/a | $19.98 | - | 1 | Mar 4, 2020 | |
| NKTR Nektar Therapeutics | Initiates: Overweight | n/a | $1.32 | - | 1 | Mar 4, 2020 | |
| EDIT Editas Medicine | Upgrades: Buy | n/a | $5.32 | - | 1 | Jan 23, 2018 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Buy | n/a | $53.91 | - | 1 | Jan 23, 2018 | |
| AFMD Affimed | Initiates: Buy | $70 | $5.03 | +1,291.65% | 1 | Jul 14, 2017 |
Exelixis
Apr 11, 2024
Downgrades: Equal-Weight
Price Target: $25
Current: $23.70
Upside: +5.49%
MacroGenics
Mar 8, 2024
Maintains: Overweight
Price Target: $23 → $25
Current: $14.56
Upside: +71.70%
TScan Therapeutics
Mar 7, 2024
Maintains: Overweight
Price Target: $7 → $9
Current: $7.32
Upside: +22.95%
Arvinas
Feb 29, 2024
Maintains: Overweight
Price Target: $26 → $60
Current: $32.37
Upside: +85.36%
Iovance Biotherapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $18 → $22
Current: $11.64
Upside: +89.00%
SpringWorks Therapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $47 → $63
Current: $45.53
Upside: +38.37%
Fate Therapeutics
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $3.80
Upside: +163.16%
Blueprint Medicines
Feb 13, 2024
Maintains: Equal-Weight
Price Target: $58 → $70
Current: $93.00
Upside: -24.73%
Replimune Group
Dec 6, 2023
Maintains: Overweight
Price Target: $50 → $13
Current: $6.42
Upside: +102.49%
Exscientia
Oct 17, 2023
Maintains: Overweight
Price Target: $12 → $10
Current: $4.03
Upside: +148.14%
Adaptimmune Therapeutics
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.08
Upside: -6.98%
Prelude Therapeutics
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.07
Upside: +22.85%
Syndax Pharmaceuticals
Jul 26, 2023
Maintains: Overweight
Price Target: $31 → $34
Current: $21.06
Upside: +61.44%
Biomea Fusion
May 12, 2023
Initiates: Overweight
Price Target: $50
Current: $10.78
Upside: +363.82%
Relay Therapeutics
Apr 19, 2023
Maintains: Equal-Weight
Price Target: $23 → $15
Current: $6.37
Upside: +135.48%
Nurix Therapeutics
Mar 9, 2023
Initiates: Overweight
Price Target: $20
Current: $12.36
Upside: +61.81%
Deciphera Pharmaceuticals
Jan 4, 2023
Maintains: Underweight
Price Target: $8 → $9
Current: $14.65
Upside: -38.57%
Arcus Biosciences
Dec 21, 2022
Maintains: Overweight
Price Target: $60 → $35
Current: $15.55
Upside: +125.08%
Immunocore Holdings
Nov 30, 2022
Initiates: Overweight
Price Target: $80
Current: $58.46
Upside: +36.85%
NexImmune
Aug 16, 2022
Maintains: Overweight
Price Target: $175 → $50
Current: $3.37
Upside: +1,383.68%
Karyopharm Therapeutics
Aug 5, 2022
Maintains: Overweight
Price Target: $14 → $8
Current: $1.06
Upside: +654.72%
Bicycle Therapeutics
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $22.73
Upside: +31.98%
CytomX Therapeutics
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $1.59
Upside: +120.13%
Illumina
Aug 6, 2021
Maintains: Underweight
Price Target: n/a
Current: $122.28
Upside: -
Agios Pharmaceuticals
Oct 22, 2020
Upgrades: Overweight
Price Target: n/a
Current: $31.49
Upside: -
Xencor
Mar 4, 2020
Initiates: Underweight
Price Target: n/a
Current: $19.98
Upside: -
Nektar Therapeutics
Mar 4, 2020
Initiates: Overweight
Price Target: n/a
Current: $1.32
Upside: -
Editas Medicine
Jan 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $5.32
Upside: -
CRISPR Therapeutics AG
Jan 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $53.91
Upside: -
Affimed
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $5.03
Upside: +1,291.65%